Skip to main content
Premium Trial:

Request an Annual Quote

Hematogenix FDA Approved PD-L1 Companion Diagnostic Test

Hematogenix Laboratory Services is offering two US Food and Drug Administration approved PD-L1 companion diagnostic assays: PD-L1 IHC 22C3 pharmDx for Keytruda and PD-L1 IHC 28-8 pharmDx. Dako, an Agilent company, developed PD-L1 IHC 22C3 pharmDx Keytruda in partnership with Merck. Keytruda is approved by the FDA to treat patients with metastatic non-small cell lung cancer whose tumors express PD-L1 and have disease progression on or after platinum-containing chemotherapy. PD-L1 IHC 28-8 pharmDx, also developed by Dako, was approved as a companion diagnostic for Bristol-Myers Squibb's Opdivo, to detect PD-L1 protein expression levels and to help physicians determine which patients may benefit most from treatment with the therapy. Both kits are available through Dako.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.